
About Intarcia
Intarcia is a Healthcare company based in Boston (United States) founded in 1995. Osmotic mini-pumps for subcutaneous drug delivery are developed. Intarcia has raised $1.89 billion across 22 funding rounds from investors including Fidelity Investments, SVB and Gates. The company has 68 employees. Intarcia was last valued at $3.5 billion in December 2020. Its focus areas include Life Sciences, Diabetes, Drugs and Drug Delivery. Its legal entity is INTARCIA THERAPEUTICS, INC. Its competitors include Sana Biotechnology, Semma Therapeutics and Rezolute; 2 of its 3 listed competitors have raised funding.
Company details
Intarcia Therapeutics was founded in 1995 in Boston, United States, within the biotechnology sector. A platform technology for drug delivery is provided, featuring subcutaneous osmotic mini-pumps. These devices are implanted under the skin and filled with the required drug volume. Extracellular fluid water enters the pump, generating osmotic pressure that propels a piston to release the drug steadily over time. Operations focus on this implantation-based delivery method.
- Headquarters Boston, United States
- Employees 68
- Stage Unicorn
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website intarcia.com
- Social LinkedIn X
- Legal Name Intarcia Therapeutics, Inc.
- Total Equity Funding$1.89B (USD)
in 22 rounds
- Latest Funding Round$198.5M (USD), Series J
Jan 2020
- InvestorsFidelity Investments
& 42 more
- Employee Count68
Funding Insights of Intarcia
Intarcia has successfully raised a total of $1.89B across 22 strategic funding rounds. The most recent funding activity was a Series J round of $198.5 million completed in January 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.89B
- Total Rounds 22
- Last Round Series J β $198.5M
- First Round $38M
(Sep 2000)
- Investors Count 43
Latest 10 of 22 funding rounds of Intarcia with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2020 | $198.5M | Series J | β | β | β |
| Jan 2018 | $8M | Series J | β | Ascent Venture Partners | |
| Aug 2017 | $524.6M | Series J | β | Gates Foundation | β |
| Jan 2017 | $50M | Series J | β | Gates Foundation | β |
| Jan 2017 | $90M | Grant | β | β | |
| May 2016 | $75M | Debt – Conventional | β | β | |
| Jun 2015 | $300M | Series J | $5.5B | β | β |
| Apr 2014 | $200M | Series I | β | RA Capital Management | |
| Nov 2012 | $50M | Debt – Conventional | β | β | |
| Nov 2012 | $160M | Series H | β | New Leaf Venture Partners, Venrock |
| Date | Valuation | Stage |
|---|---|---|
| Jun 2015 | $5.5B | β’β’β’β’β’β’β’β’ |
Full valuation and stage history of Intarcia
Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.
- All valuation points
- Stage changes
- Dates
- Exports
Verified entity values are shown only after access is granted.
Last known valuation $3.5B (Dec 2020). 43 investors in total: 43 institutional.
Investors in Intarcia
Intarcia has secured backing from 43 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments, SVB and Gates.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
US focused early-stage VC firm | ascentvp.com | Bedford, United States | ||
Venture capital investments in early stage B2B software and academic research startups. | osagepartners.com | |||
| nxtventures.com | ||||
Private debt funds are managed across multiple sectors. | 2008 | midcapfinancial.com | Bethesda, United States | |
Multiple investment strategies are pursued by this hedge fund. | 1986 | faralloncapital.com | San Francisco, United States | |
Multi-stage investment firm invests in healthcare and life sciences companies | foresitecapital.com | New York, United States | ||
ESG investments are managed by this venture capital firm. | 1964 | alger.com | New York, United States | |
Stage-agnostic investments in US life sciences are managed. | 2005 | nlvpartners.com | New York, United States | |
PE firm backed by quilvest group | quilvestprivateequity.com | Las Condes, Chile | ||
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States |
Investor details for Intarcia
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Intarcia
10 people are tracked at Intarcia (5 in leadership, 5 in team); the tracked headcount is 68.
| Name | Role | Group |
|---|---|---|
Karina N. | Executive Director, Corporate Controller | Leadership |
Kesete Kifle | Director, MSAT Corporate Validation | Leadership |
Habeeb O. | Director, Clinical Data Manager | Leadership |
Bing Yang | Vice President, Pharmaceutical Sciences | Leadership |
Debra Platek | Senior Director, Device Design | Leadership |
Malachy O'Dornan | Senior Project Manager | Team |
Louise Lu | Sr. Data Reviewer | Team |
Sandra Miyahara | Environmental, Health, and Safety | Team |
Cristiana Eftimie | Senior Scientist | Team |
Marivic Matias | Quality Control Data Specialist | Team |
Complete people profiles for Intarcia
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Intarcia
4 dated milestones of Intarcia across 25 years, from founding to its latest funding, stage changes and deals.
- Founded Intarcia is founded.
- Funding First funding round of $38.0M.
- Milestone Reaches Unicorn status.
- Funding Latest funding round, Series J, of $198.5M.
Competitors of Intarcia
Intarcia has 3 listed competitors in our database, 2 of them funded. They include Sana Biotechnology, Semma Therapeutics and Rezolute.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sana.com | 2018 | Seattle, United States | $821M | 328 | Genetically engineered cell therapies are developed for multiple disorders. | |
| semma-tx.com | 2015 | Cambridge, United States | $158M | 58 | Provider of bio-artificial pancreas for Type 1 Diabetes treatment | |
| rezolutebio.com | 2012 | Denver, United States | 51 | Therapies for metabolic and orphan diseases are developed by Rezolute. |
Detailed competitors of Intarcia
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Intarcia
Websites that share an audience with Intarcia (intarcia.com).
Websites whose visitors overlap most with Intarcia. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| edgetherapeutics.com | 100% | View details | |||
| addextherapeutics.com | 97% | 3.3K | #7,605,013 | View details | |
| argostherapeutics.com | 96% | View details | |||
| g1therapeutics.com | 96% | 2.8K | #6,603,375 | View details | |
| abeonatherapeutics.com | 95% | 8K | #2,941,685 | View details | |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 13 similar websites and full traffic analytics for Intarcia
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 13 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Diabetes
3 companies that operate in the same segment as Intarcia (Diabetes) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of devices for continuous glucose monitoring and manual insulin delivery | 2008 | San Diego, California, United States | USD 100.73 M | USD 1.02 B | 2,650 | |
Wearable glucose monitoring patches are provided for real-time data tracking. | 1999 | San Diego, California, United States | USD 52.5 M | USD 4.66 B | 10,300 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Intarcia
Complete news archive for Intarcia
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Intarcia
Intarcia was founded in 1995 and raised its 1st funding round 5 years after it was founded.
Intarcia is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Intarcia is a funded company, having raised a total of $1.89B across 22 funding rounds to date. The company's 1st funding round was a Debt β Conventional of $50M, raised on Sep 2000.
Intarcia has 68 employees.
Intarcia Therapeutics was founded in 1995 in Boston, United States, within the biotechnology sector. A platform technology for drug delivery is provided, featuring subcutaneous osmotic mini-pumps. These devices are implanted under the skin and filled with the required drug volume. Extracellular fluid water enters the pump, generating osmotic pressure that propels a piston to release the drug steadily over time. Operations focus on this implantation-based delivery method.
Intarcia's top competitors include Sana Biotechnology, Semma Therapeutics and Rezolute.
Intarcia has 43 investors. Key investors include Fidelity Investments, SVB, Gates, New Leaf Venture Partners, and Franklin Templeton.
The valuation of Intarcia is $3.5B as of Dec 2020.
Intarcia operates through Intarcia Therapeutics, Inc..
